Loading clinical trials...

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT01156025

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.

Lead sponsor: Laboratoires Thea•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment16

Start dateMar 2009

Last updatedJul 2, 2010

Condition

Acute Adenoviral Keratoconjunctivitis

Locations shown

Medical Director

Clermont-Ferrand

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 2, 2010Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions